Suppr超能文献

羟氯喹对减轻手骨关节炎症状的有效性:一项随机试验。

Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis: A Randomized Trial.

机构信息

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, United Kingdom (S.R.K., A.G., R.J.W., P.G.C.).

York Trials Unit, University of York, York, United Kingdom (P.T., A.K., S.J.R., C.A.).

出版信息

Ann Intern Med. 2018 Mar 20;168(6):385-395. doi: 10.7326/M17-1430. Epub 2018 Feb 20.

Abstract

BACKGROUND

Synovitis is believed to play a role in producing symptoms in persons with hand osteoarthritis, but data on slow-acting anti-inflammatory treatments are sparse.

OBJECTIVE

To determine the effectiveness of hydroxychloroquine versus placebo as an analgesic treatment of hand osteoarthritis.

DESIGN

Randomized, double-blind, placebo-controlled clinical trial with 12-month follow-up. (ISRCTN registry number: ISRCTN91859104).

SETTING

13 primary and secondary care centers in England.

PARTICIPANTS

Of 316 patients screened, 248 participants (82% women; mean age, 62.7 years) with symptomatic (pain ≥4 on a 0- to 10-point visual analogue scale) and radiographic hand osteoarthritis were randomly assigned and 210 (84.7%) completed the 6-month primary end point.

INTERVENTION

Hydroxychloroquine (200 to 400 mg) or placebo (1:1) for 12 months with ongoing usual care.

MEASUREMENTS

The primary end point was average hand pain during the previous 2 weeks (on a 0- to 10-point numerical rating scale [NRS]) at 6 months. Secondary end points included self-reported pain and function, grip strength, quality of life, radiographic structural change, and adverse events. Baseline ultrasonography was done.

RESULTS

At 6 months, mean hand pain was 5.49 points in the placebo group and 5.66 points in the hydroxychloroquine group, with a treatment difference of -0.16 point (95% CI, -0.73 to 0.40 point) (P = 0.57). Results were robust to adjustments for adherence, missing data, and use of rescue medication. No significant treatment differences existed at 3, 6, or 12 months for any secondary outcomes. The percentage of participants with at least 1 joint with synovitis was 94% (134 of 143) on grayscale ultrasonography and 59% on power Doppler. Baseline structural damage or synovitis did not affect treatment response. Fifteen serious adverse events were reported (7 in the hydroxychloroquine group [3 defined as possibly related] and 8 in the placebo group).

LIMITATION

Hydroxychloroquine dosage restrictions may have reduced efficacy.

CONCLUSION

Hydroxychloroquine was no more effective than placebo for pain relief in patients with moderate to severe hand pain and radiographic osteoarthritis.

PRIMARY FUNDING SOURCE

Arthritis Research UK.

摘要

背景

人们认为滑膜炎在手骨关节炎患者产生症状中起作用,但关于慢作用抗炎药的治疗数据很少。

目的

确定羟氯喹与安慰剂作为手骨关节炎的镇痛治疗的有效性。

设计

随机、双盲、安慰剂对照临床试验,随访 12 个月。(ISRCTN 注册号:ISRCTN86475734)。

地点

英格兰 13 个初级和二级保健中心。

参与者

在 316 名筛查患者中,248 名(82%为女性;平均年龄 62.7 岁)有症状(疼痛≥视觉模拟量表 0-10 分中的 4 分)和放射照相手骨关节炎的患者被随机分配,210 名(84.7%)完成了 6 个月的主要终点。

干预措施

羟氯喹(200 至 400 毫克)或安慰剂(1:1)治疗 12 个月,同时进行常规护理。

测量

主要终点是 6 个月时过去 2 周内平均手部疼痛(0-10 分数字评分量表[NRS])。次要终点包括自我报告的疼痛和功能、握力、生活质量、放射照相结构变化和不良事件。进行基线超声检查。

结果

在 6 个月时,安慰剂组的平均手部疼痛为 5.49 分,羟氯喹组为 5.66 分,治疗差异为-0.16 分(95%CI,-0.73 至 0.40 分)(P=0.57)。调整依从性、缺失数据和使用救援药物后,结果仍然稳健。在 3、6 或 12 个月时,任何次要结局均无显著治疗差异。在灰阶超声检查中,至少有 1 个关节有滑膜炎的参与者百分比为 94%(134/143),而在功率多普勒中为 59%。基线结构损伤或滑膜炎并不影响治疗反应。报告了 15 例严重不良事件(羟氯喹组 7 例[3 例定义为可能相关],安慰剂组 8 例)。

局限性

羟氯喹的剂量限制可能降低了疗效。

结论

羟氯喹在手痛和放射照相性骨关节炎中度至重度患者中缓解疼痛的效果并不优于安慰剂。

主要资金来源

关节炎研究英国。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验